Takeda』s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
OSAKA, Japan & CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) for ......
